Physician profile
Gavin D Stormont
NPI 1639690589
$3,241.15
in general payments reported to CMS, 2019-2025
29 companies · $51.38 in 2025
The $51.38 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $317 · 2021: $626 · 2022: $879 · 2023: $694 · 2024: $673 · 2025: $51.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Travel and Lodging: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.60 |
| Travel and Lodging | $273.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $556.60 | 2020-2025 | Axonics |
| Teleflex LLC | $478.31 | 2022-2025 | Urolift, Barrigel |
| Procept Biorobotics Corporation | $406.89 | 2024 | Aquabeam System |
| Coloplast Corp | $246.10 | 2020-2023 | Speedicath, Titan |
| Neotract INC. | $232.92 | 2020 | |
| Axonics, INC. | $196.79 | 2021-2024 | Axonics |
| Olympus America INC. | $154.34 | 2022-2023 | Itind System, Soltive |
| 180 Medical, INC. | $119.63 | 2023-2024 | Speedicath, Gentlecath Glide, Gentlecath |
| Ethicon US, LLC | $95.96 | 2022 | |
| Accord Healthcare, INC. | $82.11 | 2022-2024 | |
| Photocure INC | $71.78 | 2022-2023 | Cysview |
| Astellas Pharma US INC | $65.77 | 2022-2024 | Xtandi |
| Karl Storz Endoscopy-America | $65.28 | 2022 | |
| Antares Pharma, INC. | $63.57 | 2022-2024 | Xyosted |
| Medtronic, INC. | $55.31 | 2022-2023 | Interstim |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $54.22 | 2023-2024 | |
| Abbvie INC. | $44.29 | 2022-2024 | Botox |
| Progenics Pharmaceuticals, INC. | $43.92 | 2023-2024 | Pylarify |
| Convatec INC. | $39.47 | 2022-2023 | |
| Halozyme INC | $30.08 | 2023 | |
| Janssen Biotech, INC. | $26.44 | 2022-2023 | Akeega, Erleada |
| Dendreon Pharmaceuticals LLC | $22.07 | 2021 | |
| Sumitomo Pharma America, INC. | $16.35 | 2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $16.10 | 2023 | Lynparza |
| Blue Earth Diagnostics | $15.79 | 2024 | |
| Tolmar, INC. | $15.70 | 2023 | |
| Laborie Medical Technologies Corp. | $13.77 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Clinical Technology, INC | $11.59 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$200,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Stormont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.